Claudia Sievers
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Plasma neurofilament light, glial fibrillary acidic protein and lysosphingolipid biomarkers for pharmacodynamics and disease monitoring of GM2 and GM1 gangliosidoses patients.
Journal: Molecular genetics and metabolism reports
Published: December 13, 2021
Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium.
Journal: PLoS medicine
Published: January 24, 2020
PARP-1 deregulation in multiple sclerosis.
Journal: Multiple sclerosis journal - experimental, translational and clinical
Published: June 14, 2019
Prediction of natalizumab anti-drug antibodies persistency.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: January 17, 2018
Monocyte NOTCH2 expression predicts IFN-β immunogenicity in multiple sclerosis patients.
Journal: JCI insight
Published: December 19, 2017
Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis.
Journal: Journal of autoimmunity
Published: August 12, 2017
Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: November 05, 2015
MiR-126: a novel route for natalizumab action?
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 07, 2014
Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.
Journal: Journal of immunology research
Published: November 28, 2013
Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects.
Journal: Clinical immunology (Orlando, Fla.)
Published: February 16, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026